Fresenius SE & Co. KGaA (FSNUF)
- Previous Close
37.50 - Open
35.50 - Bid 35.17 x 45100
- Ask 37.70 x 40000
- Day's Range
35.50 - 35.50 - 52 Week Range
25.77 - 37.50 - Volume
2,773 - Avg. Volume
182 - Market Cap (intraday)
20.432B - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
40.34 - EPS (TTM)
0.88 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date May 18, 2023
- 1y Target Est
8.04
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der H?he, Germany.
www.fresenius.com177,091
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: FSNUF
View More
Performance Overview: FSNUF
Trailing total returns as of 11/12/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FSNUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FSNUF
View MoreValuation Measures
Market Cap
20.22B
Enterprise Value
31.35B
Trailing P/E
40.70
Forward P/E
9.48
PEG Ratio (5yr expected)
0.23
Price/Sales (ttm)
0.82
Price/Book (mrq)
1.00
Enterprise Value/Revenue
1.28
Enterprise Value/EBITDA
9.62
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.68%
Return on Assets (ttm)
1.51%
Return on Equity (ttm)
1.44%
Revenue (ttm)
22.81B
Net Income Avi to Common (ttm)
-479M
Diluted EPS (ttm)
0.88
Balance Sheet and Cash Flow
Total Cash (mrq)
1.49B
Total Debt/Equity (mrq)
68.63%
Levered Free Cash Flow (ttm)
14.62B
Research Analysis: FSNUF
View MoreCompany Insights: FSNUF
FSNUF does not have Company Insights
Research Reports: FSNUF
View MoreMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, checking in on the hotel REIT recovery; looking at Palo Alto's strengths and weaknesses; where generative AI can pay off for patient investors; and Fresenius SE, British American Tobacco, and Nio.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, checking in on the hotel REIT recovery; looking at Palo Alto's strengths and weaknesses; where generative AI can pay off for patient investors; and Fresenius SE, British American Tobacco, and Nio.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, obesity drug's effect on dialysis may be muted; looking at the upcoming commercial real estate cycle; and taking the US economic pulse; and Amcor PLC, Sinopharm Group, and Hennes & Mauritz.
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, Westpac going in right direction; Morningstar retiring moat trend rating; Corteva on right path; and Guardant Health, Fresenius SE, and Intellia Therapeutics.